Almirall notes "good traction in Europe" for psoriasis cream Wynzora

The Spanish skin health firm’s psoriasis business continues to grow in H1, driven in part by the cream dubbed Wynzora, which was developed by MC2 Therapeutics.

Photo: Almirall / PR

Psoriasis cream Wynzora has gotten off to a flying start on the European market, winning 7% and 6% market shares in Germany and Spain, respectively, reports the Spanish dermatology firm that sells the treatment, Almirall, in connection with its H1 report.

Almirall’s core net sales, counting its Medical Dermatology portfolio, have increased 5% in the first half of 2022 to EUR 437m, while the firm’s earnings before interest, taxes, depreciation and amortizations (EBITDA) amounted to EUR 108m, which is a 22% drop compared to last year that was boosted by product divestments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs